drugset / Trial / NCT06532578
Evaluate the Safety and Efficacy of CPX101 in Overweight and Obese Subjects Without Diabetes Mellitus
RandomizedParallel-groupDouble-blindTreatment
Summary
The study is designed to evaluate the preliminary efficacy, safety, population PK profile, and immunogenicity of CPX101 in subjects with obesity or overweight with weight related comorbidities but without diabetes mellitus.
Timeline
- Start
- 2024-08-13
- Primary completion
- 2025-12-15
- Completion
- 2026-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CPX101 | Unknown | 120 mg | Subcutaneous |
| Subject | CPX101 | Unknown | 160 mg | Subcutaneous |
| Subject | CPX101 | Unknown | 320 mg | Subcutaneous |
| Subject | CPX101 | Unknown | 360 mg | Subcutaneous |